Skip to main content
. 2015 Apr 21;21(15):4644–4651. doi: 10.3748/wjg.v21.i15.4644

Figure 2.

Figure 2

Virologic, biochemical, and histologic efficacy at week 48 among treated patients with evaluable hepatic hepatitis B virus DNA pairs. 1ALT < 1.25 × upper limit of normal; 2≥ 2-point decrease in Knodell necroinflammatory score with no worsening (≥ 1-point increase from baseline) of Knodell fibrosis score; 3≥ 1-point decrease in Ishak fibrosis score from baseline.